|
π
|
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
18 auth.
P. Caimi,
W. Ai,
J. Alderuccio,
K. Ardeshna,
M. Hamadani,
B. Hess,
B. Kahl,
J. Radford,
M. Solh,
A. Stathis,
...
P. Zinzani,
K. Havenith,
J. Feingold,
Shui He,
Y. Qin,
D. Ungar,
Xiaoyan Zhang,
C. Carlo-Stella
|
7 |
2021 |
7
π
|
|
π
|
The IL-15-Based ALT-803 Complex Enhances FcΞ³RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
21 auth.
M. Rosario,
Bai Liu,
Lin Kong,
Lynne I Collins,
Stephanie E. Schneider,
Xiaoyue Chen,
Kai-ping Han,
Emily K. Jeng,
P. Rhode,
Jeffrey W. Leong,
...
Timothy Schappe,
B. Jewell,
Catherine R. Keppel,
Keval Shah,
B. Hess,
R. Romee,
D. Piwnica-Worms,
A. Cashen,
N. Bartlett,
H. Wong,
T. Fehniger
|
7 |
2015 |
7
π
|
|
π
|
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
42 auth.
J. Zurko,
J. Ramdial,
M. Shadman,
Saira S. Ahmed,
A. Szabo,
L. Iovino,
A. A. Tomas,
C. Sauter,
M. Perales,
N. Shah,
Utkarsh H Acharya,
C. Jacobson,
R. Soiffer,
T. Wang,
K. Komanduri,
...
S. Jaglowski,
A. Kittai,
N. Denlinger,
M. Iqbal,
M. Kharfan-Dabaja,
E. Ayala,
J. Chavez,
M. Jain,
F. Locke,
Yazeed Samara,
L. Budde,
M. Mei,
A. D. Pia,
T. Feldman,
N. Ahmed,
R. Jacobs,
N. Ghosh,
Bhagirathbhai R. Dholaria,
O. Oluwole,
B. Hess,
Ayesha Hassan,
V. Kenkre,
P. Reagan,
F. Awan,
Y. Nieto,
M. Hamadani,
A. Herrera
|
5 |
2022 |
5
π
|
|
π’
|
Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies
12 auth.
James A. Davis,
Katelynn Granger,
K. Roubal,
Deidra Smith,
K. Gaffney,
M. McGann,
...
Alyssa M Cendagorta,
A. Thurlapati,
A. Herbst,
L. Hendrickson,
Hamza Hashmi,
B. Hess
|
5 |
2022 |
5
π’
|
|
π
|
Patients With Venous Thromboembolism Appear to Have Higher Prevalence of Obstructive Sleep Apnea Than the General Population
7 auth.
James P. Bosanquet,
B. Bade,
Maryam F Zia,
Ammar Karo,
O. Hassan,
B. Hess,
...
O. Dabbagh
|
5 |
2011 |
5
π
|
|
π
|
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.
32 auth.
P. Torka,
S. Kothari,
S. Sundaram,
Shaoying Li,
L. Medeiros,
E. Ayers,
D. Landsburg,
D. Bond,
K. Maddocks,
Anshu Giri,
B. Hess,
Luu Q. Pham,
R. Advani,
Yang Liu,
S. Barta,
...
J. Vose,
M. Churnetski,
Jonathon B. Cohen,
M. Burkart,
R. Karmali,
J. Zurko,
A. Mehta,
A. Olszewski,
Sarah S Lee,
B. Hill,
T. Burns,
F. Lansigan,
E. Rabinovich,
D. Peace,
A. Groman,
K. Attwood,
F. Hernandez-Ilizaliturri
|
5 |
2020 |
5
π
|
|
π
|
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
15 auth.
Sushanth Gouni,
A. Rosenthal,
J. Crombie,
A. Ip,
M. Kamdar,
B. Hess,
Lei Feng,
G. Watson,
A. Ayers,
S. Neelapu,
...
A. Khurana,
Yi Lin,
M. Iqbal,
R. Merryman,
P. Strati
|
4 |
2022 |
4
π
|
|
π
|
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
16 auth.
P. Caimi,
W. Ai,
J. Alderuccio,
K. Ardeshna,
M. Hamadani,
B. Hess,
B. Kahl,
J. Radford,
M. Solh,
A. Stathis,
...
P. Zinzani,
Ying Wang,
Y. Qin,
Luqiang Wang,
Zhiying Cindy Xu,
C. Carlo-Stella
|
4 |
2023 |
4
π
|
|
π
|
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
26 auth.
J. Foltz,
B. Hess,
V. Bachanova,
N. Bartlett,
M. Berrien-Elliott,
Ethan McClain,
M. Becker-Hapak,
M. Foster,
Timothy Schappe,
B. Kahl,
N. Mehta-Shah,
A. Cashen,
Nancy D. Marin,
Kristen McDaniels,
Chaz Moreno,
...
Matthew Mosior,
F. Gao,
O. Griffith,
M. Griffith,
Julia A Wagner,
N. Epperla,
A. Rock,
John H. Lee,
A. Petti,
P. Soon-Shiong,
T. Fehniger
|
4 |
2021 |
4
π
|
